TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3728125

Group type: EXPERIMENTAL
Intervention: Experimental treatment program consisting of communication and counseling skills, assertiveness training, and moral dilemmas.
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 54
Study: 28678033

Group type: EXPERIMENTAL
Intervention: Myofascial Release Therapy (MRT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Physical Therapy (PT)
Number of subjects: 41
Study: 26811178

Group type: EXPERIMENTAL
Intervention: gemcitabine/carboplatin (GC)
Number of subjects: 55

Group type: COMPARATOR
Intervention: docetaxel/carboplatin (DC)
Number of subjects: 55
Study: 24994700

Group type: EXPERIMENTAL
Intervention: Group S (n = 38): Chest tubes removed if PrRPl/B ≤0.5, regardless of daily drainage.
Number of subjects: 72

Group type: COMPARATOR
Intervention: Group C (n = 34): Chest tubes removed if daily drainage ≤250 ml, regardless of protein content.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Group S vs Group C: Mean chest tube removal time.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Group S vs Group C: Median hospital stay.
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Group S: Patients with high protein content preventing removal despite acceptable volume of daily drainage.
Number of subjects: 72
Study: 23232895

Group type: EXPERIMENTAL
Intervention: Acetazolamide (750 mg/d) + autoCPAP
Number of subjects: 51
Study: 20694273

Group type: COMPARATOR
Intervention: Warfarin (dose-adjusted to a target INR of 2.0-3.0)
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg bid
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg bid
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg qd
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg qd
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Edoxaban (both 30 and 60 mg qd)
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1146
Study: 18245547

Group type: EXPERIMENTAL
Intervention: EGF vaccine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supportive care (Control)
Number of subjects: 80
Study: 16813794

Group type: EXPERIMENTAL
Intervention: Magnifying endoscopy with acetic acid-guided biopsies
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard video endoscopy with random biopsies
Number of subjects: 31
Study: 12629372

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rofecoxib 25 mg
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 10945085

Group type: EXPERIMENTAL
Intervention: Supervision Register policy (registered patients)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Comparison patients (upper tier of the Care Programme Approach)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Clinicians' views on the Supervision Register policy
Number of subjects: 259
Study: 9103749

Group type: EXPERIMENTAL
Intervention: Behavioral counseling plus physical exercise (BEX; n = 72)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Behavioral counseling plus nicotine gum (BNIC; n = 63)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Standard treatment (ST) American Lung Association quit program plus nicotine anonymous meetings (n = 70)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: All groups (BEX, BNIC, ST)
Number of subjects: 205
Study: 8250305

Group type: COMPARATOR
Intervention: Placebo (HS)/placebo (AM)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: 20 mg of famotidine (HS)/20 mg of famotidine (AM)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: 20 mg of famotidine (HS)/placebo (AM)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Placebo (HS)/20 mg of famotidine (AM)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: 40 mg of famotidine (HS)/40 mg of famotidine (AM)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: 40 mg of famotidine (HS)/placebo (AM)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Placebo (HS)/40 mg of famotidine (AM)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Famotidine (HS and AM or AM only)
Number of subjects: 322
Study: 3892672

Group type: EXPERIMENTAL
Intervention: Paractol flüssig
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sab simplex
Number of subjects: 20
Study: 30139340

Group type: EXPERIMENTAL
Intervention: Postoperative intravenous infusion of somatostatin for 6 days
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo infusion for 6 days
Number of subjects: 152
Study: 27386006

Group type: EXPERIMENTAL
Intervention: Dill seed oil mouthrinse
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate mouthrinse (Hexodent)
Number of subjects: 90
Study: 24880672

Group type: EXPERIMENTAL
Intervention: Phonosurgery/voice therapy
Number of subjects: 40
Study: 22672686

Group type: EXPERIMENTAL
Intervention: 20% aluminum particle filled PMMA
Number of subjects: 10

Group type: COMPARATOR
Intervention: unfilled PMMA
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: aluminum and silver fillers in concentrations of 10%, 20%, and 30%
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: silane-treated metalized PMMA at 30% concentration
Number of subjects: 10
Study: 20356558

Group type: EXPERIMENTAL
Intervention: 3% NaCl solution
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 4.5% NaCl solution
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 6% NaCl solution
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 7.5% NaCl solution
Number of subjects: 75

Group type: COMPARATOR
Intervention: 0.9% NaCl solution (control group)
Number of subjects: 75
Study: 19029562

Group type: EXPERIMENTAL
Intervention: IV ketamine plus midazolam (1 mg/kg ketamine + 0.1 mg/kg midazolam; IVKM)
Number of subjects: 99

Group type: COMPARATOR
Intervention: IV ketamine only (1 mg/kg; IVK)
Number of subjects: 99
Study: 15718178

Group type: EXPERIMENTAL
Intervention: C+HBI
Number of subjects: 106

Group type: COMPARATOR
Intervention: UC
Number of subjects: 106
Study: 12873948

Group type: EXPERIMENTAL
Intervention: Tramadol plus diclofenac (100 mg tramadol and 75 mg diclofenac IM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Tramadol plus placebo (100 mg tramadol IM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diclofenac plus placebo (75 mg diclofenac IM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Double placebo (tramadol plus diclofenac)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tramadol plus diclofenac
Number of subjects: 120

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 120
Study: 11798619

Group type: EXPERIMENTAL
Intervention: mecobalamin 500 microg intramuscularly three times a week for four weeks then followed by 500 microg orally three times a day for additional eight weeks
Number of subjects: 108

Group type: COMPARATOR
Intervention: vitamin B(12)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: mecobalamin
Number of subjects: 108
Study: 8601552

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU b.i.d.)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 1746779

Group type: EXPERIMENTAL
Intervention: Transderm scopolamine
Number of subjects: 201

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study: 6138055

Group type: EXPERIMENTAL
Intervention: Loprazolam (1.0 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg body weight)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Loprazolam (1.0 mg) + Alcohol (0.7 g/kg body weight)
Number of subjects: 8
Study: 31894413

Group type: EXPERIMENTAL
Intervention: Moderate-intensity intermittent exercise in the heat (400 W, 15-min bouts with 15-min recovery)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Moderate-intensity intermittent exercise in the heat
Number of subjects: 33
Study: 31189966

Group type: COMPARATOR
Intervention: Sulfonylurea treatment (any type)
Number of subjects: 47738

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 47738

Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 47738
Study: 29127562

Group type: EXPERIMENTAL
Intervention: Active videogame for 30 min, once a week for 6 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sedentary videogame for 30 min, once a week for 6 weeks
Number of subjects: 28
Study: 27593569

Group type: COMPARATOR
Intervention: Standard therapy sessions
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Child-focused therapy sessions
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Context-focused therapy sessions
Number of subjects: 49
Study: 25152474

Group type: EXPERIMENTAL
Intervention: CoreValve transcatheter heart valve delivered by subclavian artery (n = 70)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CoreValve transcatheter heart valve delivered by direct aortic approach (n = 80)
Number of subjects: 150
Study: 22170010

Group type: EXPERIMENTAL
Intervention: Candesartan (± thiazide‐diuretics)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Candesartan (± thiazide‐diuretics) with diuretics
Number of subjects: 252
Study: 20122030

Group type: EXPERIMENTAL
Intervention: Oncologist communication with older patients
Number of subjects: 180
Study: 17470267

Group type: EXPERIMENTAL
Intervention: Educational intervention to promote childbirth companions in 5 hospitals
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group (5 hospitals without the educational intervention)
Number of subjects: 2000
Study: 15089025

Group type: EXPERIMENTAL
Intervention: Heel lift group
Number of subjects: 198

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study: 12205249

Group type: EXPERIMENTAL
Intervention: Nurse
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: Paraprofessional
Number of subjects: 735

Group type: COMPARATOR
Intervention: Control
Number of subjects: 735
Study: 11477829

Group type: EXPERIMENTAL
Intervention: Qiangxinling liquid extract (QXLLE)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Qiangxinling liquid extract (QXLLE) plus small dose of digoxin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Group A and B
Number of subjects: 90
Study: 8586726

Group type: EXPERIMENTAL
Intervention: PCR detection of CMV DNA in serum
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 52
Study: 2694331

Group type: EXPERIMENTAL
Intervention: Octatropine-methyl-bromide and sulglycotide salt (GVP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 355877

Group type: EXPERIMENTAL
Intervention: Vitamin E administration (intramuscularly)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no vitamin E)
Number of subjects: 40
Study: 31862739

Group type: EXPERIMENTAL
Intervention: Oral valganciclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical 2% ganciclovir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27725233

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA) injection (10 cc)
Number of subjects: 30
Study: 26542471

Group type: EXPERIMENTAL
Intervention: Health Evaluation and Referral Assistant (HERA)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: Health Evaluation and Referral Assistant (HERA) with faxed referral
Number of subjects: 421

Group type: COMPARATOR
Intervention: Minimal-treatment Control
Number of subjects: 421
Study: 23868858

Group type: EXPERIMENTAL
Intervention: RA appendage ON (n=98)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: RA appendage OFF (n=99)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: RA septum ON (n=92)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: RA septum OFF (n=96)
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Continuous atrial overdrive pacing ON
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: Continuous atrial overdrive pacing OFF
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: RA septum pacing
Number of subjects: 385

Group type: COMPARATOR
Intervention: RA appendage pacing
Number of subjects: 385
Study: 21411291

Group type: EXPERIMENTAL
Intervention: Hilotherm water-circulating cooling device
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional cooling by cold packs
Number of subjects: 0
Study: 19634964

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 160
Study: 17668528

Group type: EXPERIMENTAL
Intervention: Retinoid-containing combination regimens with oral antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retinoid-containing combination regimens with topical benzoyl peroxide and antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noncomparative studies of retinoid-containing regimens
Number of subjects: 0
Study: 14871220

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid-PDT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laser and PDT
Number of subjects: 20
Study: 11260098

Group type: EXPERIMENTAL
Intervention: Continuous wound perfusion of local bupivacaine 0.5 per cent for 60 hours
Number of subjects: 70

Group type: COMPARATOR
Intervention: Intermittent intravenous morphine infusion on demand (PCA group)
Number of subjects: 70
Study: 9557932

Group type: EXPERIMENTAL
Intervention: Irbesartan 100 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enalapril 20 mg once daily
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 20
Study: 7849233

Group type: EXPERIMENTAL
Intervention: Formulation B (solution)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Formulation A (powder)
Number of subjects: 14
Study: 3071461

Group type: EXPERIMENTAL
Intervention: Ketanserin (up to 80 mg daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketanserin (8 weeks administration)
Number of subjects: 24
Study: 28562435

Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA) treatment
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 114
Study: 26756882

Group type: EXPERIMENTAL
Intervention: Cantilevered RBFPD (CL2)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fixed-fixed RBFPD (FF3)
Number of subjects: 28
Study: 24179984

Group type: EXPERIMENTAL
Intervention: Solvent removal using paper point and light-curing methods (cocuring for 40 s, adhesive cured for 20 s, adhesive cured for 40 s, intracanal tip for 20 s)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Solvent removal using air-drying method and light-curing methods (cocuring for 40 s, adhesive cured for 20 s, adhesive cured for 40 s, intracanal tip for 20 s)
Number of subjects: 80
Study: 22092997

Group type: EXPERIMENTAL
Intervention: Oral zinc sulphate (3 × 200 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (4 patients without treatment)
Number of subjects: 14
Study: 20858692

Group type: EXPERIMENTAL
Intervention: Current practice plus information aid (personal interview with a physician using a navigable compact disc and a take-home booklet)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Current practice (diagnosis disclosure)
Number of subjects: 120
Study: 19102147

Group type: EXPERIMENTAL
Intervention: Shoulder-elbow elastic band immobilization and functional exercise
Number of subjects: 75

Group type: COMPARATOR
Intervention: Forearm-suspending band immobilization and functional exercise therapy
Number of subjects: 75
Study: 16907901

Group type: EXPERIMENTAL
Intervention: Benzocaine/tyrothricin sucking lozenges with conscious sedation
Number of subjects: 174

Group type: COMPARATOR
Intervention: Conscious sedation alone
Number of subjects: 174
Study: 12521968

Group type: EXPERIMENTAL
Intervention: Assessment and intervention
Number of subjects: 274

Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 274
Study: 11375586

Group type: EXPERIMENTAL
Intervention: Minilaparoscopy (ML)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL)
Number of subjects: 104
Study: 10322831

Group type: EXPERIMENTAL
Intervention: Combined therapy of Xuefu Zhuyu decoction and move stripe field radiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo and radiotherapy
Number of subjects: 0
Study: 8435382

Group type: EXPERIMENTAL
Intervention: Torasemide (20 mg/day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Furosemide (50 mg/day)
Number of subjects: 7
Study: 3304118

Group type: EXPERIMENTAL
Intervention: terodiline (50 mg/d)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: emepronium (600 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 28952873

Group type: EXPERIMENTAL
Intervention: Self-determination theory-based dance program
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Self-determination theory-based walking program
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 35
Study: 28533679

Group type: COMPARATOR
Intervention: rosuvastatin 20 mg alone
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg plus EGCG 300 mg on Day 4
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg plus EGCG 300 mg on Day 15
Number of subjects: 13
Study: 25644997

Group type: EXPERIMENTAL
Intervention: Targeted recruitment letter with health risk information specific to their racial/ethnic group (n = 216)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Standard letter with risk information for the general population (n = 229)
Number of subjects: 445
Study: 24135131

Group type: EXPERIMENTAL
Intervention: Basic version of Featback (psychoeducation and fully automated monitoring and feedback system)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic version of Featback with infrequent support (weekly e-mail, chat, or Skype support from a coach)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic version of Featback with frequent support (three times a week e-mail, chat, or Skype support from a coach)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 0
Study: 21164127

Group type: EXPERIMENTAL
Intervention: 25% albumin (ALB)
Number of subjects: 434

Group type: COMPARATOR
Intervention: saline (placebo)
Number of subjects: 434
Study: 18234132

Group type: EXPERIMENTAL
Intervention: Intentional weight loss
Number of subjects: 11

Group type: COMPARATOR
Intervention: Lifestyle interventions (intentional weight loss)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 11
Study: 17163254

Group type: EXPERIMENTAL
Intervention: Etidronic acid (400 mg/day for 24 weeks)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no etidronic acid therapy)
Number of subjects: 14
Study: 12665756

Group type: EXPERIMENTAL
Intervention: Peppermint oil solution administered intraluminally
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hyoscine‐N‐butylbromide injection
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo solution administered intraluminally
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo solution administered intramuscularly
Number of subjects: 100
Study: 10719808

Group type: EXPERIMENTAL
Intervention: Late addition of G-CSF (250 microg) from day 8 after cyclophosphamide (4 g/m2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Early addition of G-CSF (250 microg) from day 2 after cyclophosphamide (4 g/m2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Late addition of G-CSF
Number of subjects: 30

Group type: COMPARATOR
Intervention: Early addition of G-CSF
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 9196130

Group type: EXPERIMENTAL
Intervention: Topotecan (1.5 mg/m2 as a 30‐minute infusion daily for 5 days every 21 days)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Paclitaxel (175 mg/m2 infused over 3 hours every 21 days)
Number of subjects: 226
Study: 30852486

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine Zhiyi decoction combined with acupuncture
Number of subjects: 84

Group type: COMPARATOR
Intervention: Traditional Chinese medicine Zhiyi decoction
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (Traditional Chinese medicine Zhiyi decoction)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Study group (Zhiyi decoction + acupuncture)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study: 28883543

Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND) high in fiber/whole grain
Number of subjects: 62

Group type: COMPARATOR
Intervention: Average Danish Diet (ADD)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Comparison of responsiveness to diets
Number of subjects: 62
Study: 26877998

Group type: EXPERIMENTAL
Intervention: Tympanoplasty without malleus lifting
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tympanoplasty with malleus lifting
Number of subjects: 30
Study: 24865795

Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (PCST)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 256
Study: 22480387

Group type: EXPERIMENTAL
Intervention: Olanzapine-fluoxetine combination (6/50-18/50 mg/d)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Fluoxetine (50 mg/d)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Olanzapine (6-18 mg/d)
Number of subjects: 205
Study: 18465716

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (TA)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sub-Tenon block (STB)
Number of subjects: 59
Study: 16973303

Group type: EXPERIMENTAL
Intervention: Hypofractionation (used in 41 patients, 73%)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional fractionation (used in 15 patients, 27%)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Hypofractionation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 56
Study: 12760627

Group type: EXPERIMENTAL
Intervention: Utterance format variation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0